Custom procedural convenience kits and trays, general hospital use, labeled as: a) Baby PICC Kit, kit number UIBP90J; b) Baby PICC Kit, kit number UIBP90K; c) PORT PACK (PS 058330), kit number UIPO82AB; d) Pediatric PICC Kit, kit number UIPP76K;
Publicado el 7 de febrero de 2024 · Inicio del retiro: 29 de noviembre de 2023
Resumen
FDA registra el retiro Z-0826-2024 de dispositivos médicos de Clase II, publicado el 7 de febrero de 2024 e iniciado el 29 de noviembre de 2023. Empresa responsable: American Contract Systems, Inc.; Estado: En curso; Cantidad reportada: 244 units; Lote: a) UIBP90J, UDI/DI 00191072117038, Lot Numbers: 996231, exp. 1/4/2024; b) UIBP90K, UDI/DI 00191072189356, Lot Numbers: 911231, exp. 7/26/2023; c) UIPO82AB, UDI/DI 00191072172006, Lot Numbers: 727221, exp. 9/30/2023; 680221, exp. 11/16/2023; d) UIPP76K, UDI/DI 00191072142849, Lot Numbers: 637221, exp. 12/29/2023; 976231, exp. 1/24/2024; 898231, exp. 4/12/2024. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Ongoing — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
During an internal investigation, ACS identified that several components were "piggybacked" to ACS trays and subjected to the ACS sterilization process. There is no supporting documentation stating the "piggybacked" components were assessed to determine if they were suitable for exposure to elevated temperatures for an extended period of time and further exposure to sterilization. As a result, the piggybacked components may (1) have a loss/lack of functionality, (2) loss of drug efficacy, if applicable, and (3) may have had higher than specified EO residuals.
Qué hacer
Voluntary: Firm initiated · E-Mail
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- American Contract Systems, Inc.
- Distribuidor
- US Nationwide distribution.
- Lote
- a) UIBP90J, UDI/DI 00191072117038, Lot Numbers: 996231, exp. 1/4/2024; b) UIBP90K, UDI/DI 00191072189356, Lot Numbers: 911231, exp. 7/26/2023; c) UIPO82AB, UDI/DI 00191072172006, Lot Numbers: 727221, exp. 9/30/2023; 680221, exp. 11/16/2023; d) UIPP76K, UDI/DI 00191072142849, Lot Numbers: 637221, exp. 12/29/2023; 976231, exp. 1/24/2024; 898231, exp. 4/12/2024
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDABrand Name: Banner University Med Ctr. Product Name: Cardiac Cath Lab Pack-170278 Model/Catalog Number:2 de abril de 2025
- FDAHand Pack, AKHD97C; Medical convenience kit2 de octubre de 2024
- FDAVaginal Delivery, ASDV25B; Medical convenience kit2 de octubre de 2024
- FDAIR Procedure Pack, CEAT19W; Medical convenience kit2 de octubre de 2024
- FDACustom procedural convenience kits and trays, general & plastic surgery, labeled as: a) BRACHY THERAPY7 de febrero de 2024
- FDACustom procedural convenience kits and trays, general hospital use, labeled as: a) IR NEURO PACK, kit number7 de febrero de 2024
Preguntas sobre este retiro
¿Custom procedural convenience kits and trays, general hospital use, labeled as: a) Baby PICC Kit, kit number UIBP90J; b) Baby PICC Kit, kit number UIBP90K; c) PORT PACK (PS 058330), kit number UIPO82AB; d) Pediatric PICC Kit, kit number UIPP76K; fue retirado del mercado?
Sí. FDA publicó el retiro Z-0826-2024 el 7 de febrero de 2024. Peligro reportado: During an internal investigation, ACS identified that several components were "piggybacked" to ACS trays and subjected to the ACS sterilization process. There is no supporting documentation stating the "piggybacked" components were assessed to determine if they were suitable for exposure to elevated temperatures for an extended period of time and further exposure to sterilization. As a result, the piggybacked components may (1) have a loss/lack of functionality, (2) loss of drug efficacy, if applicable, and (3) may have had higher than specified EO residuals.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · E-Mail